Sildisoft Tablets, containing sildenafil citrate, are widely known for their role in treating erectile dysfunction (ED) and pulmonary arterial hypertension (PAH). While they offer significant short-term benefits, concerns persist regarding their potential long-term effects on health. Understanding these implications is crucial for users and healthcare providers alike to make informed decisions. This article explores the short-term and potential long-term effects of Sildisoft Tablets, shedding light on important considerations for users. Sildisoft Tablets are primarily composed of sildenafil citrate, a phosphodiesterase type 5 (PDE5) inhibitor. This compound works by relaxing muscles and increasing blood flow to specific areas of the body, primarily aiding in achieving and maintaining an erection in men with ED. Additionally, it helps in managing PAH by relaxing blood vessels in the lungs, reducing the workload on the heart.